Librela is a veterinary medicine used to alleviate pain associated with osteoarthritis in dogs. For some dogs it produces a significant improvement in comfort, mobility and quality of life. Other dogs show little improvement, and a small proportion experience suspected adverse effects.
The potential benefits and risks should be considered for the individual dog, particularly when treating an elderly dog or one with neurological, immune-mediated or other existing health problems.
What is Librela?
Librela contains bedinvetmab, a canine monoclonal antibody. It is given by injection beneath the skin, normally once a month, by a veterinary professional.
Bedinvetmab targets canine nerve growth factor, usually abbreviated to NGF. NGF is involved in pain signalling. By binding to NGF, Librela reduces the osteoarthritis pain signals reaching the nervous system.
Librela is intended to relieve pain. It does not rebuild damaged cartilage or cure osteoarthritis.
What is a monoclonal antibody?
Antibodies are proteins that bind to specific targets. A monoclonal antibody medicine is designed to bind to one particular target—in this case, canine nerve growth factor.
Librela is not a conventional painkiller such as a non-steroidal anti-inflammatory drug. It is processed differently by the body and does not carry exactly the same risks. However, this does not mean that it is free from possible adverse effects.
Possible benefits
- Reduced pain associated with osteoarthritis.
- Improved willingness to walk, rise, climb steps or interact.
- Improved mobility and quality of life in dogs that respond well.
- Monthly administration rather than tablets given every day.
- A possible option for some dogs unable to tolerate other pain medicines.
Some owners report dramatic improvements, with an older dog becoming more active and interested in normal life again. For a dog whose quality of life is being seriously affected by osteoarthritis, this improvement can be extremely valuable.
Not every dog responds. If there is no meaningful improvement after treatment, the veterinary surgeon should reassess the diagnosis and pain-management plan.
Pain relief and increased activity
When pain is reduced, a dog may attempt more exercise than its weakened muscles and arthritic joints can safely manage. Increased activity does not mean that the underlying joint disease has disappeared.
Exercise should be increased gradually. Weight control, suitable surfaces, controlled exercise, physiotherapy and appropriate muscle strengthening remain important.
Contact your veterinary surgeon if a dog develops new or increased joint swelling, joint pain or lameness after treatment. The current product information advises that further investigation and discontinuation may need to be considered on an individual basis.
Officially recognised adverse reactions
The current UK product information lists adverse reactions according to how frequently they have been reported.
| Frequency | Recognised reactions |
|---|---|
| Uncommon 1 to 10 dogs in 1,000 treated |
Injection-site reactions such as swelling or warmth. |
| Rare 1 to 10 dogs in 10,000 treated |
Diarrhoea, vomiting, ataxia, increased urination, urinary incontinence, loss of appetite, lethargy and increased thirst. |
| Very rare Fewer than 1 dog in 10,000 treated, including isolated reports |
Hypersensitivity reactions, immune-mediated haemolytic anaemia, immune-mediated polyarthritis, immune-mediated thrombocytopenia, joint swelling, joint pain, bone or joint disorders, soft-tissue ossification, paresis, paralysis and seizures. |
These frequency categories describe suspected adverse reactions reported across the treated population. They do not predict what will happen to an individual dog.
Dogs requiring particular consideration
Dogs with a seizure disorder
The official product information advises caution when treating a dog with a pre-existing seizure disorder. Any history of seizures, tremors, collapse or unexplained neurological episodes should be discussed before treatment.
Dogs with immune-mediated disease
The veterinary surgeon should know if the dog has, or previously had, an immune-mediated condition. Very rare immune-mediated reactions have been reported.
Dogs receiving other pain medicines
There are no safety data for the concurrent long-term use of non-steroidal anti-inflammatory drugs and bedinvetmab in dogs. Owners should not add, restart or alter another pain medicine without veterinary instructions.
Pregnant or breeding animals
Librela should not be used in animals intended for breeding or in pregnant or lactating dogs. The veterinary surgeon should be told if breeding is planned or possible.
The UK regulator’s 2026 assessment
In February 2026, the UK Veterinary Medicines Directorate published an in-depth assessment following concerns about serious events reported after Librela treatment.
The VMD identified a small subset of dogs aged six years or over that deteriorated rapidly within 14 days of treatment. Many had neurological signs, but there was no consistent pattern and some had previously received Librela for years.
The VMD concluded that it remained unclear whether those deteriorations were caused by Librela.
The assessment also identified a small subset of reports in which arthritis appeared to progress faster than expected. These reports represented a very rare frequency of fewer than one dog per 10,000 estimated dogs treated.
Reports made after a medicine is given are important signals and should be investigated, but timing alone does not prove causation. Dogs receiving Librela are often elderly and may have several illnesses that can worsen independently.
Owner-reported experiences
Owners have shared a wide range of experiences following Librela injections. Some report a major improvement in comfort and mobility with few or no obvious adverse effects.
Others report symptoms that began after the first injection or after several months of treatment. Reports shared with veterinary surgeons, regulators and owner groups have included:
- Lethargy or unusual tiredness.
- Increased thirst or urination.
- Urinary incontinence.
- Reduced appetite or refusal of food.
- Vomiting or diarrhoea.
- Drooling, trembling or shaking.
- Changes in behaviour, fearfulness or hiding.
- Staggering, ataxia or falling over.
- Weakness of the hindquarters or difficulty standing.
- Seizures or an increase in existing seizures.
- New or worsening joint pain, swelling or lameness.
Some of these symptoms now appear in the official product information as rare or very rare adverse reactions. Others may also be caused by osteoarthritis, age-related disease, spinal problems, organ disease or another medicine.
An owner’s report should not be dismissed, but it does not by itself establish that Librela caused the event.
Librela Experiences Facebook group
Facebook groups can provide useful owner experiences and emotional support, but reports are not verified clinical evidence and should not replace examination by a veterinary surgeon.
When to contact the veterinary surgeon
Seek prompt veterinary advice if a dog develops any unexpected change after treatment, particularly:
- Difficulty standing, severe weakness or collapse.
- Staggering, loss of balance, paralysis or a seizure.
- New or rapidly worsening lameness or joint swelling.
- Repeated vomiting or diarrhoea.
- Refusal of food or water.
- Markedly increased thirst or urination.
- Loss of bladder control.
- Facial swelling, widespread itching or difficulty breathing.
- Pale gums, unexplained bruising or bleeding.
- A significant change in behaviour or alertness.
Severe weakness, collapse, seizures, paralysis, breathing difficulty or facial swelling require urgent veterinary attention.
Do not wait for a suspected reaction to wear off without seeking advice.
Before each injection
Before another injection is given, tell the veterinary surgeon about every change noticed since the previous dose, even if it appears unrelated.
It may be helpful to keep a simple record including:
- The date of each injection.
- Mobility before and after treatment.
- Appetite and water consumption.
- Urination and continence.
- Vomiting or diarrhoea.
- Behaviour and alertness.
- Any weakness, trembling or loss of balance.
- Other medicines and supplements being given.
Short videos of the dog walking, rising and using steps can help the owner and veterinary surgeon judge whether treatment is producing a worthwhile improvement.
Questions to discuss with your vet
- Has osteoarthritis been confirmed as the cause of the pain?
- Could spinal, neurological or other disease be contributing?
- What improvement should reasonably be expected?
- How and when will the response be assessed?
- Does the dog have an existing seizure or immune-mediated disorder?
- Could another medicine or supplement interact with the treatment plan?
- What symptoms should prevent another injection being given?
- What alternatives are available if Librela is ineffective or unsuitable?
Reporting a suspected adverse reaction
Suspected adverse reactions can be reported even when it is uncertain whether Librela caused the problem.
Owners can ask their veterinary surgeon to submit a report or report directly to the Veterinary Medicines Directorate. Useful information includes treatment dates, batch details, symptoms, test results, other medicines and the eventual outcome.
Report a suspected problem with an animal medicine
Other ways to support a dog with osteoarthritis
Osteoarthritis usually benefits from a combined approach rather than reliance upon one injection or tablet. Depending upon the dog, this may include:
- Maintaining a healthy, lean body weight.
- Regular controlled exercise.
- Physiotherapy or hydrotherapy where appropriate.
- Rugs or non-slip flooring.
- Ramps and supportive bedding.
- Other veterinary pain medicines.
- Veterinary rehabilitation and muscle-strengthening exercises.
- Joint supplements as an addition to, rather than a replacement for, necessary treatment.
My experience with “Joints” from Vince the Vet
I have had a lot of success with my older dogs using a product called Joints from Vince the Vet.
This is my own experience and does not mean that every dog will respond in the same way. A nutritional supplement is not a direct alternative to Librela or prescribed pain relief for every dog, but it may be one part of a wider joint-care plan.
Owners should tell their veterinary surgeon about every supplement being given, particularly when a dog has other medical conditions or receives prescribed medication.
Balancing benefits and risks
There is no answer that is right for every dog. Librela may provide valuable relief and extend a good quality of life for some dogs with painful osteoarthritis.
For other dogs, it may provide little benefit or be followed by suspected adverse effects. This is why the dog’s response and general health should be reviewed before treatment continues.
A balanced decision should consider:
- How much pain is affecting the dog’s quality of life.
- Whether Librela produces a meaningful improvement.
- The dog’s age and other health conditions.
- Any new symptoms following an injection.
- Alternative treatments and their own possible risks.
- The owner’s observations and priorities for the dog.
Official information and further reading
NOAH Compendium – current Librela clinical information
Veterinary Medicines Directorate – Librela assessment
VMD – detailed assessment results
European Medicines Agency – March 2026 Librela safety update
VMD – report a suspected adverse reaction
Veterinary disclaimer: This article provides general information and includes owner-reported and personal experiences. It is not a substitute for veterinary diagnosis or treatment.
Do not stop, start or combine prescribed medicines without consulting your veterinary surgeon. Seek urgent assistance if a dog develops severe weakness, collapse, breathing difficulty, paralysis or seizures.
This article reflects UK product information and regulatory assessments available in July 2026. Veterinary medicine information may be updated as new safety data are evaluated.